ArticleFrontiers in molecular biosciences2025
A LODDS-based nomogram for overall and cancer-specific survival in stage III-IV gastric signet ring cell carcinoma.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The prognostic value of log odds of positive lymph nodes in patients with resectable locally advanced gastric cancer following neoadjuvant therapy: results from the SEER database.Translational cancer research · 2026Article
- Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer.Journal of gastrointestinal oncology · 2026Article
- Optimizing gastric cancer treatment: the role of LODDs in lymph node staging.Frontiers in oncology · 2026Article
- A log odds of positive lymph nodes (LODDS)-based nomogram for survival prediction in elderly bladder cancer patients after radical cystectomy: development and validation using SEER and Chinese cohorts.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gastric cancer is a serious human chronic disease. The gastric signet ring cell carcinoma (GSRCC) is the most-dangerous subtype with several acute complications, including gastrointestinal hemorrhage, gastric perforation, pyloric obstruction and so on. This study aimed to compare the predictive efficiency of positive lymph nodes (PLN) and log odds of positive lymph nodes (LODDS) for survival and to establish a LODDS-based nomogram model in stage III-IV GSRCC. Methods: Stage III-IV GSRCC patients were acquired between 2015 and 2019 from SEER dataset and the affiliated Yixing hospital of jiangsu university, serving as training and validation datasets respectively. The X-tile software was used to identify cut-off values while their relationship with clinical features was explored by chi-square test. The Kaplan-Meier analysis was applied for survival curve while cox regression analysis was performed for independent risk factors. The nomogram model was built with ROC and calibration curves for verification. Results: A total of 585 stage III-IV GSRCC patients were included in this study with 536 patients for training and 49 patients for validation. The LODDS showed better predictive efficiency for overall survival (OS) and cancer-specific survival (CSS) than PLN. The LODDS, M stage and chemotherapy status were independent factors for both OS and CSS, with LODDS contribution accounting for 31.47% in OS and 30.39% in CSS. A LODDS-based nomogram was built with accurate efficiency in stage III-IV GSRCC. The 1-year, 2-year, 3-year OS area under curve (AUC) values were 0.755, 0.795, 0.759 for internal and 0.776, 0.756, 0.816 for external verification while 1-year, 2-year, 3-year CSS AUC values were 0.745, 0.803, 0.770 for internal and 0.796, 0.762, 0.820 for external verification. Conclusion: LODDS is an independent risk factor in stage III-IV GSRCC. The LODDS-based nomogram model showed excellent predictive efficiency, providing a novel insight for early diagnosis and precise therapies of stage III-IV GSRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.